Related Experiment Video

Updated: May 15, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.2K

Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment

Zhengfei Guo1, Richard W Dong2, Yusheng Wu1

  • 1TYK Medicines, Inc., Huzhou, Zhejiang, 313100, China.

Oncogene
|April 8, 2025
PubMed

Insights

Targeting cyclin-dependent kinase 4 and 6 (CDK4/6) shows promise in breast cancer treatment. This review explores resistance mechanisms and combination strategies to overcome acquired resistance to CDK4/6 inhibitors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Breast cancer is a leading cause of cancer mortality globally, particularly in women.
  • Aberrant cyclin-dependent kinase 4 and 6 (CDK4/6) pathway activation drives uncontrolled breast cancer cell proliferation.
  • CDK4/6 inhibitors are approved for hormone receptor-positive, HER2-negative metastatic breast cancer, demonstrating significant success.

Purpose of the Study:

  • To systematically review the mechanisms of acquired resistance to CDK4/6 inhibitors in breast cancer.
  • To analyze combination strategies to enhance the efficacy of CDK4/6 inhibitors.

Main Methods:

  • Systematic review of existing literature on CDK4/6 inhibitor resistance.
  • Analysis of cell cycle-specific and cell cycle-nonspecific resistance mechanisms.
  • Evaluation of preclinical and clinical data on combination therapies.

Main Results:

  • Identified diverse mechanisms contributing to acquired resistance to CDK4/6 inhibitors.
  • Highlighted the potential of combining CDK4/6 inhibitors with other targeted agents.
  • Demonstrated that combination strategies can overcome resistance and improve therapeutic outcomes.

Conclusions:

  • Understanding resistance mechanisms is crucial for improving CDK4/6 inhibitor therapy.
  • Combination strategies offer a promising approach to enhance clinical applications of CDK4/6 inhibitors.
  • Further research into combination therapies may lead to improved survival rates for breast cancer patients.

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.4K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.5K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K